Overview

Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.

Status:
RECRUITING
Trial end date:
2040-12-01
Target enrollment:
Participant gender:
Summary
The study is for patients with advanced melanoma who are eligible for standard therapy with Pembrolizumab.
Phase:
PHASE2
Details
Lead Sponsor:
Eikon Therapeutics
Collaborator:
Merck Sharp & Dohme LLC
Treatments:
pembrolizumab